Although the majority of antibiotics will be unable to help the effects of COVID-19, a recent study has shown that the antibiotic, Azithromycin is currently being investigated as a potential treatment. According to the WHO, Azithromycin has anti-inflammatory effects that might help to reduce an overactive immune response to COVID-19. The drug has previously been effective in preventing severe bacterial respiratory tract infections in children with viral infections.
In order to scale up its production of its adjuvant for use in potential COVID-19 vaccines, Dynavax received an investment from the Bill & Melinda Gates Foundation.
With the investment, Dynavax plans to establish the capacity to produce up to 750 million adjuvanted doses per year.
Currently, estimates of the incubation period for COVID-19 are around 4-5 days. However, NIH have now led a study that has allowed researchers to formulate a new and longer estimated incubation time. Using data from patients who contracted the virus in Wuhan, China, it has been discovered that the median incubation period for COVID-19 was actually 7.76 days.
A team of scientists from the University of California, Riverside recently developed a machine learning drug discovery pipeline. This new discovery pipeline is a type of computational strategy linked to artificial intelligence and aims to hopefully identify hundreds of new potential drugs that could help treat COVID-19.
Having developed an antibody cocktail to fight COVID-19, Regeneron Pharmaceuticals aims to post their initial biomarker data from its clinical trials next month. Like other developers, Regeneron are also testing its product in the prevention against COVID-19. The prevention program will put Regeneron up against vaccines that may be more durable, however the company believe that there is a gap in the immunization market for its antibody cocktail.